| MCM Teams With Executive To Acquire Platform Investment
(Life Science Industry) |
MCM Capital is pleased to partner with a seasoned executive to identify potential acquisitions and investment opportunities within the life science or medical device industry.
For the past eight years he has held various executive positions at Thermo Fisher Scientifc a leading supplier of laboratory supplies and life science products. Most recently he was the President of HyClone, a Thermo Fisher Scientific Company. Hyclone is a manufacturer of cell culture media, sera and bioprocess container systems. Prior to Hyclone, he served as President of Nalge Nunc International, a manufacturer of high purity packaging, cell culture plastics, and general lab and consumer products for biotech and life science applications.
Types of Businesses: manufacturers of engineered components and consumables sold into the life science and medical device industries.
Annual Revenues: $15 million+
EBITDA Margins: 15%+
Location: North America
MCM is pleased to pay standard intermediary fees for any lead culminating in a transaction. Should you become aware of an opportunity that fits within MCM's criteria please contact Mark Mansour or Bobby Kingsbury.
.
|
|
Sincerely,
MCM Capital Partners |
| About Us
MCM Capital Partners, founded in 1992, is a Cleveland, Ohio based MicroCap private equity firm investing in lower middle-market companies generating revenues between $15 million and $75 million. Over the past seventeen years, MCM has successfully partnered with strong management teams in buyout and recapitalization transactions of niche manufacturing, specialty service, and value-added distribution companies.
|
